Immunotherapy plus chemotherapy for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests a new combination of two drugs for advanced pancreatic cancer. It aims to see if adding an immunotherapy drug (which helps your immune system attack cancer) to standard chemotherapy can help control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have pancreatic cancer that has spread or cannot be removed, and it must have gotten worse after at least one previous treatment.
- You must have not had immunotherapy or gemcitabine chemotherapy before.
- You must have at least one tumor that can be measured on a scan.
- You must be generally well enough to care for yourself (ECOG score 0-1).
- Your major organs (blood, liver, kidneys, heart) must be working well, as shown by lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy medicine (adebrelimab) added to standard care for people with pancreatic cancer that has caused fluid buildup in the belly or around the lungs. The goal is to see if this combination can help control the cancer and reduce the fluid buildup.
This trial tests a new medicine (IBI363) combined with chemotherapy for people with advanced pancreatic cancer that has grown after their first treatment. The goal is to see if this combination can help shrink or control the cancer longer.
This trial tests whether adding an immunotherapy drug (sintilimab) to standard chemotherapy before and after surgery helps shrink tumors and improve outcomes for people with pancreatic cancer that can be removed.
This trial tests a combination of immunotherapy (adebelimab) and chemotherapy drugs (irinotecan liposome, oxaliplatin, fluorouracil, and calcium folinate) as a first treatment for pancreatic cancer that has spread to the liver. The goal is to see if this combination is safe and effective.
This trial tests a new drug called IBI343 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests combining cryoablation (freezing tumors) with a dual-antibody drug (PD-1/CTLA-4) for people whose locally advanced pancreatic cancer has stopped responding to first-line chemotherapy (AG regimen). The goal is to see if this combination can help control the cancer.
Hear when a new Pancreatic Cancer Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.